Journal
JOURNAL OF CONTROLLED RELEASE
Volume 337, Issue -, Pages 179-192Publisher
ELSEVIER
DOI: 10.1016/j.jconrel.2021.07.018
Keywords
Dendrimer; Glioblastoma; Tumor-associated macrophages; Glycosylation; Tumor-targeting
Funding
- Arnall Patz Distinguished Professorship endowment
- NEI [R01 EY025304]
- NINDS [R01NS093416]
- Wilmer Core Grant for Vision, Research, Microscopy, and Imaging Core Module [P30EY001765]
Ask authors/readers for more resources
The research explores the use of sugar moieties conjugated to dendrimers for targeted therapy of glioblastoma and other cancers. Glucose modification significantly enhances targeting of tumor-associated macrophages and microglia, while galactose modification shifts targeting towards galectins on glioblastoma tumor cells.
Glioblastoma is among the most aggressive forms of cancers, with a median survival of just 15-20 months for patients despite maximum clinical intervention. The majority of conventional anti-cancer therapies fail due to associated off-site toxicities which can be addressed by developing target-specific drug delivery systems. Advances in nanotechnology have provided targeted systems to overcome drug delivery barriers associated with brain and other types of cancers. Dendrimers have emerged as promising vehicles for targeted drug and gene delivery. Dendrimer-mediated targeting strategies can be further enhanced through the addition of targeting ligands to enable receptor-specific interactions. Here, we explore the sugar moieties as ligands conjugated to hydroxyl-terminated polyamidoamine dendrimers to leverage altered metabolism in cancer and immune targeting. Using a highly facile click chemistry approach, we modified the surface of dendrimers with glucose, mannose, or galactose moieties in a well-defined manner, to target upregulated sugar transporters in the context of glioblastoma. We show that glucose modification significantly enhanced targeting of tumor-associated macrophages (TAMs) and microglia by increasing brain penetration and cellular internalization, while galactose modification shifts targeting away from TAMs towards galectins on glioblastoma tumor cells. Mannose modification did not alter TAMs and microglia targeting of these dendrimers, but did alter their kinetics of accumulation within the GBM tumor. The whole body biodistribution was largely similar between the systems. These results demonstrate that dendrimers are versatile delivery vehicles that can be modified to tailor their targeting for the treatment of glioblastoma and other cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available